MMP9, matrix metallopeptidase 9, 4318

N. diseases: 1337; N. variants: 31
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.070 GeneticVariation disease BEFREE For MMP3-1171 5A>6A and MMP9-1562 C>T polymorphisms, no association was found in overall comparison; however, in subgroup analyses based on ethnicity and tumor site, significant associations were detected between the MMP3-1171 5A>6A polymorphism and HNC risk in a European population and pharyngeal/laryngeal cancer under two genetic contrasts. 23637955 2013
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.070 AlteredExpression disease BEFREE Prognostic role of MMP-9 expression in head and neck carcinoma patients treated with radiotherapy or chemoradiotherapy. 23122824 2013
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.070 AlteredExpression disease BEFREE Inactivation or loss of TTP promotes invasion in head and neck cancer via transcript stabilization and secretion of MMP9, MMP2, and IL-6. 23349315 2013
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.070 Biomarker disease BEFREE A genetically related pair of human head and neck cancer (HNSCC) cell lines derived from the same patient at different stages of disease was used to investigate the role of extracellular matrix, integrin, and CXCL12-CXCR4 receptor interactions and their signal pathways in MMP-2 and MMP-9 activation and cell invasion. 21380786 2012
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.070 GeneticVariation disease BEFREE The results showed that under dominant genetic model, MMP2 -1306 T was associated with lower susceptibility to lung cancer [odds ratio (OR) = 0.50, 95% confidence interval (CI) 0.43-0.59, P(heterogeneity) = 0.147, I(2) = 44.1%], head and neck cancer (OR = 0.53, 95% CI 0.41-0.69, P(heterogeneity) = 0.974, I(2) = 0.0%) and oesophageal cancer (OR = 0.67, 95% CI 0.55-0.80, P(heterogeneity) = 0.593, I(2) = 0.0%); MMP2-735T was associated with lower risk in lung cancer (OR = 0.65, 95%CI 0.53-0.79, P(heterogeneity) = 0.42, I(2) = 0.0%) and oesophageal cancer (OR = 0.84, 95% CI 0.70-0.99, P(heterogeneity) = 0.206, I(2) = 37.4%); MMP7 -181 AG and GG genotype carriers had an increased gastric cancer risk (OR = 1.90, 95% CI 1.43-2.51, P(heterogeneity) = 0.992, I(2) = 0.0%) and MMP9 -1562 C>T was not associated with cancer risk in the whole group analysis (OR = 0.99, 95% CI 0.91-1.08, P(heterogeneity) = 0.419, I(2) = 3.0%) and subgroup analyses. 20360147 2010
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.070 Biomarker disease BEFREE Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. 12404284 2002
CUI: C3887461
Disease: Head and Neck Carcinoma
Head and Neck Carcinoma
0.070 Biomarker disease BEFREE MMP-9 and VEGF might act co-operatively in the process of neovascularization in human head and neck cancer. 11078794 2000